Beta-Cell Replacement Therapy
Diabetes (Type 1 / Insulin-dependent)
Pre-clinicalInactive (Under Strategic Restructuring)
Key Facts
Indication
Diabetes (Type 1 / Insulin-dependent)
Phase
Pre-clinical
Status
Inactive (Under Strategic Restructuring)
Company
About Pancryos
Pancryos is a Copenhagen-based biotech developing cell therapies for diabetes, operating within the high-potential Cell & Gene Therapy sector. Founded in 2018, the company appears to be in a transitional phase, as indicated by a public statement of 'strategic restructuring' on its website. Its core value lies in its underlying scientific work and intellectual property related to beta-cell replacement, which aims to provide a functional cure for insulin-dependent diabetes. The current operational status suggests a pivot or consolidation of efforts to advance its technology platform.
View full company profile